Calidi Biotherapeutics, Inc.
CLDINYSEHealthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|---|
| Revenue | — | — | — | $45,000 | — |
| Operating income | −$20.2M | −$21.8M | −$29.0M | −$23.1M | −$1.8M |
| Net income | −$19.9M | −$22.1M | −$29.2M | −$25.4M | $3.4M |
| Total assets | $8.9M | $14.2M | $10.0M | $2.6M | $231.8M |
| Total liabilities | $5.1M | $12.2M | $18.3M | $43.4M | $16.5M |
| Equity | $3.8M | $1.5M | −$8.2M | −$50.4M | −$31.6M |
| EPS (diluted) | $-5.95 | $-2.97 | $-17.33 | $2.99 | — |
| Shares out. | 28.5M | 35.5M | 3.6M | 8.6M | 23.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −529.6%
- Return on assets
- −224.7%
- Return on capital (ROCE)
- −411.2%
- Liabilities / assets
- 57.6%
- Debt / equity
- 1.36×
- Book value / share
- $0.13
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -64.99distress
- Accruals / assets
- 15.7%high accruals
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 2 warning● 0 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- High accruals — earnings-quality risk
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 15, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Armistice Capital, LlcPassive (13G)May 15, 2026
- Gavrilov Ognian AnguelovActivist (13D)Mar 31, 2026
- Lincoln Alternative Strategies LlcPassive (13G)Feb 10, 2026
- Kessler Judd SActivist (13D)May 1, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Camaisa AllanDirector | Dec 12, 2025 | Sell | 850 | $1.46 |
| Schoeneck James ADirector | Aug 21, 2025 | Buy | 75,000 | $2.00 |
| Poma Eric EOfficer — Chief Executive Officer | Aug 21, 2025 | Buy | 25,000 | $2.00 |
| Leftwich ScottDirector | Aug 21, 2025 | Buy | 125,000 | $2.00 |
| Jackson Andrew C.Officer — Chief Financial Officer | Aug 21, 2025 | Buy | 2,500 | $2.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 670,614 | 1.0 | -77.9% |
| Apr 30, 2026 | 3.0M | 1.0 | +1004.7% |
| Apr 15, 2026 | 275,084 | 1.0 | +12.6% |
| Mar 31, 2026 | 244,357 | 1.0 | +31.0% |
| Mar 13, 2026 | 186,549 | 1.0 | +220.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Unregistered equity saleMay 29, 2026
- Results of operations · Regulation FD disclosureMay 14, 2026
- Entered a material agreement · Unregistered equity saleMay 8, 2026
- Director / officer change · Other material eventApr 2, 2026
- Results of operations · Regulation FD disclosureMar 27, 2026
- Entered a material agreement · Unregistered equity sale · Other material eventMar 11, 2026
- Regulation FD disclosureFeb 10, 2026
- Results of operations · Other material eventJan 29, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KMay 29, 2026
- SCHEDULE 13GMay 15, 2026
- 10-QMay 14, 2026
- 8-KMay 14, 2026
- 8-KMay 8, 2026
- DEFA14AApr 29, 2026
- DEF 14AApr 29, 2026
- PRE 14AApr 17, 2026
- 8-KApr 2, 2026
- SCHEDULE 13DMar 31, 2026
- 10-KMar 27, 2026
- 8-KMar 27, 2026
- 8-KMar 11, 2026
- SCHEDULE 13DMar 9, 2026
- 424B5Mar 9, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.